Removal of small nonenveloped viruses by antibody‐enhanced nanofiltration during the manufacture of plasma derivatives
Authors:
- 26 June 2006
- journal article
- Published by Wiley in Transfusion
- Vol. 46 (7) , 1143-1151
Abstract
BACKGROUND: Filters with nominal pore sizes in the nanometer range are well‐established tools for enhancing the virus safety margins of plasma‐derived products, yet intrinsically less successful for smaller viruses such as hepatitis A virus (HAV) and human parvovirus B19 (B19V). The formation of virus‐antibody complexes increases the effective size of these smaller viruses and would thus improve their removal by nanofiltration. While the principle of virus removal by antibody‐dependent nanofiltration has been demonstrated with animal antisera and viruses spiked into human plasma product intermediates, the significance of these results remains unclear due to the potential contributions of xenoanti‐bodies and/or heteroagglutination in such heterologous systems.STUDY DESIGN AND METHODS: The current study investigated antibody‐dependent virus removal by nanofiltration in a heterologous animal parvovirus system to establish the concentration dependence of the effect. In addition, the phenomenon was investigated in a homologous system with custom‐made HAV and B19V antibody–free and ‐containing human immunoglobulin intermediates. Viruses were analyzed with infectivity assays and fully validated polymerase chain reaction assays that also circumvent the obscuring effects of neutralizing antibodies with infectivity assays.RESULTS: By use of the heterologous mice minute virus and the homologous HAV and B19V systems, viruses passed the 35‐nm (Planova 35N) filter in the absence of specific antibodies. Beyond a threshold virus antibody concentration, nanofiltration resulted in effective virus removal of viruses smaller than the nominal pore size of the filter used.CONCLUSION: HAV and B19V are effectively removed by antibody‐dependent 35N nanofiltration, already at intermediate antibody concentrations well below those comparable to human plasma pools for fractionation.Keywords
This publication has 23 references indexed in Scilit:
- Parvovirus B19 transmission by a high‐purity factor VIII concentrateTransfusion, 2005
- An assay for parvovirus B19 neutralizing antibodies based on human hepatocarcinoma cell linesTransfusion, 2004
- Removal of small non‐enveloped viruses by nanofiltrationVox Sanguinis, 2004
- Alloantibody and xenoantibody cross-reactivity in transplantation1Transplantation, 2004
- Nanofiltration of single plasma donations: feasibility studyVox Sanguinis, 2003
- Parvovirus B19 transmission by heat‐treated clotting factor concentratesTransfusion, 2002
- Removal of Viruses from Human Intravenous Immune Globulin by 35 nm NanofiltrationBiologicals, 1998
- A sensitive PCR assay system for the quantitation of viral genome equivalents: human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV)Archives of Virology, 1997
- Variability in parvovirus B19 IgG levels in intravenous immunoglobulin samplesDiagnostic Microbiology and Infectious Disease, 1996
- Nanofiltration, a New Specific Virus Elimination Method Applied to High‐Purity Factor IX and Factor XI ConcentratesVox Sanguinis, 1994